Hengrui Pharma(600276) 选股宝·2025-03-25 12:01Group 1: Share Buybacks and Equity Transfers - Chipone Microelectronics plans to transfer 8.41% of its shares at a price no less than 85.71 CNY per share [1] - China First Heavy Industries' controlling shareholder intends to transfer 4% of the company [1] - Guoli Co., Ltd. plans to repurchase shares worth between 30 million to 50 million CNY, with a repurchase price not exceeding 73.47 CNY per share [1] Group 2: Investment Cooperation and Business Developments - Heng Rui Medicine has reached a licensing agreement with Merck, potentially receiving up to 1.77 billion USD in milestone payments [2] - China Energy Conservation Investment Corporation is investing approximately 470 million CNY in a 100 MW photovoltaic power generation project [3] - Shuangjie Electric has signed significant contracts totaling 1.555 billion CNY for daily operations [4] - Rongsheng Development is planning to restructure its debts [5] - Runhe Materials intends to invest 400 million CNY in a high-end organic silicon materials project in Zhuhai [6] - Guojijiang Precision Engineering plans to establish a company with an investment of 380 million CNY for a functional diamond material project [7] - Jiazhe New Energy is investing in a 100 MW/400 MWh shared energy storage project in Heilongjiang, with an estimated total investment of about 410 million CNY [7] - Wanrun Co., Ltd. has signed a project cooperation letter of intent with Sinopec Catalyst Co., Ltd. [7] Group 3: Performance Changes - Dalian Heavy Industry expects a net profit growth of 12.22% to 36.77% year-on-year in Q1 2025 [8] - Tailin Microelectronics anticipates a net profit of around 35 million CNY in Q1 2025, representing an approximate 894% year-on-year increase, achieving the best quarterly financial performance in its history [8] - CNOOC Services expects a 4.1% year-on-year net profit growth in 2024 and plans to distribute a dividend of 2.306 CNY per share [9]